Echosens introduces the new FibroScan® 502 Touch with CAP™ (Controlled Attenuation Parameter) in Asia [APASL 2012]

16/02/2012 - At the 2012 Conference of the Asian Pacific Association for the Study of the Liver (APASL) taking place this year in Taipei from February 16th to February 19th, Echosens, a pioneer and major player in non-invasive hepatic diagnosis, will present for the first time in Asia its latest product, the new FibroScan® 502 Touch, widening the range of FibroScan® devices now available.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan®provides a reliable, accurate and reproducible assessment of liver tissue stiffness. This technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency...

[...]

...About Echosens and Fibroscan 

FibroScan is designed to quantify hepatic stiffness and ultrasound attenuation (CAP™) in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives. The organization works in close cooperation with health professionals and patients’ associations to facilitate management and therapeutic monitoring of patients. To date, there are more than 500 peer-reviewed publications which attest to the efficacy of FibroScan® in clinical practice...[PDF] Echosens' Press Release -